Market News Archives

No Bubble, Just Bandwidth: Why Larry Fink Thinks AI Compute Is Wall Street’s Next Core Holding -( $AMD $AVGO $BLK $NVDA $INTC $TSM )

by John F. Heerdink, Jr. May 8, 2026 945Views 0Likes

Blackrock's (BLK) CEO Larry Fink is sketching the outlines of Wall Street’s next great asset class, and it isn’t carbon credits or crypto—it’s raw computing power, packaged for investors as neatly as a Treasury future. In the process, he is effectively anointing…

AI, Optics and Optimism: Nvidia and Corning’s High‑Speed Makeover for American Plants -( $GLW $NVDA )

by John F. Heerdink, Jr. May 8, 2026 575Views 0Likes

Nvidia’s (NVDA) new AI pact with Corning (GLW) is being sold as more than a supply deal; it’s being cast as a once‑in‑a‑generation chance to rebuild American manufacturing around glass, light and a lot of GPUs. AI Factories Meet Glass Factories Nvidia…

May 7, 2026 – Wall Street Takes a Coffee Break: Markets Catch Their Breath Before Jobs Friday -( $AMWL $HAWK $MODD $NVDA $TSLA Rise!)

by John F. Heerdink, Jr. May 7, 2026 7766Views 0Likes

U.S. stocks took a modest pause on Thursday, May 7, 2026, as investors digested record-level index moves, rising oil, another big earnings wave, and positioned ahead of Friday’s pivotal April jobs report. Equity markets today After this week’s sharp run-up that pushed…

Cash, Churn and Checkups: Reading Between the Lines of Amwell’s Q1 2026 -( $AMWL )

by John F. Heerdink, Jr. May 7, 2026 520Views 0Likes

Amwell’s (NYSE: AMWL) first-quarter scorecard reads like a classic Wall Street turnaround chapter: the top line is shrinking, but the balance sheet is fortified, losses are tightening, and management is whistling its way toward cash-flow breakeven by year-end. Cash, Costs and a…

HawkEye 360 Blasts Off: The Space-Data IPO That Punched 30% Above Orbit -( $ASTS $HAWK $LUNR $PL $RDW $SPCE )

by John F. Heerdink, Jr. May 7, 2026 639Views 0Likes

Space analytics firm HawkEye 360, now trading on the New York Stock Exchange under the ticker HAWK, made its public-market debut with the kind of trajectory IPO bankers dream about, as the stock jumped roughly 30% from its 26 dollar offering price on…

FMC Sells a Good Business (On Purpose): The $350 Million Spring‑Cleaning Move -( $FMC )

by John F. Heerdink, Jr. May 7, 2026 707Views 0Likes

FMC Corporation’s (FMC) latest portfolio pruning reads less like distress and more like a gardener trimming a healthy hedge so the roses can breathe. FMC Hands Off the Non‑Crop Keys FMC Corporation has signed a definitive agreement to sell its (GSS)…

Golden Arches, Golden Quarter: How McDonald’s Turned Fries Into Free Cash Flow -( $MCD $SPY $DIA )

by John F. Heerdink, Jr. May 7, 2026 401Views 0Likes

McDonald’s (MCD) kicked off 2026 reminding investors that the Golden Arches are still a finely tuned cash machine, serving up earnings and revenue beats even as consumers count pennies and trade down on everything but fries. McDonald’s Serves an Earnings Beat With…

May 6, 2026 – Oil Cools, AI Melts Up: Markets Decide War Is Bad but GPUs Are Better -( $AMD $AMWL $EBAY $EPRX $GME $NVDA $TSLA Rise!)

by John F. Heerdink, Jr. May 6, 2026 7642Views 0Likes

U.S. equities extended their AI-fueled winning streak on Wednesday, May 6, with the major indices pushing deeper into record territory as chip stocks, easing oil ($95.63/bbl,-6.49%), and a budding “peace premium” outweighed lingering rate and inflation worries. Indices and risk tone The…

A $50,000 Seat to History: Fox Sports Turns World Cup Fandom Into a Full-Time ‘Human Algorithm’ Job -( $FOX )

by John F. Heerdink, Jr. May 6, 2026 583Views 0Likes

In a move that blurs the line between sports passion and paid profession, Fox Sports (FOX) has unveiled what may be the most enviable job listing of the year: $50,000 for one devoted fan willing to watch every single match of the…

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. May 6, 2026 564Views 0Likes

Eupraxia’s (NASDAQ: EPRX) latest data drop puts eosinophilic esophagitis (EoE) firmly at center stage, with fresh endoscopic and long‑term clinical results suggesting EP‑104GI could emerge as a once‑yearly, procedure‑based alternative to chronic biologic regimens such as Sanofi’s (SNY) multi-billion dollar weekly-injectable drug…

Market News

Your Guide To Staying Informed In The Markets